AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 466
- Registration Number
- NCT00324363
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Arthralgia During Anastrozole Therapy for Breast Cancer
Phase 4
Completed
- Conditions
- Early Breast Cancer
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 114
- Registration Number
- NCT00323479
- Locations
- 🇫🇷
Research Site, Poitiers, France
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1329
- Registration Number
- NCT00322452
- Locations
- 🇹🇭
Research Site, Songkla, Thailand
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
Phase 3
Completed
- Conditions
- Generalized Anxiety Disorder
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2008-12-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT00322595
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
Phase 2
Completed
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: Goserelin acetate
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT00322348
- Locations
- 🇺🇦
Research Site, Uzhgorod, Ukraine
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00320268
- Locations
- 🇺🇸
Research Site, Brown Deer, Wisconsin, United States
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00321490
- Locations
- 🇺🇸
Research Site, Morgantown, West Virginia, United States
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
Phase 2
Completed
- Conditions
- Locally Advanced Prostate Cancer
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT00319787
- Locations
- 🇳🇴
Research Site, Trondheim, Norway
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2009-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT00319306
- Locations
- 🇬🇧
Research Site, Yaxley, United Kingdom
Nexium RESPONSE Trial
Phase 4
Completed
- Conditions
- GERD
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2009-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00318968
- Locations
- 🇩🇰
Research Site, Viby J, Denmark
© Copyright 2025. All Rights Reserved by MedPath